Title:Expression of a Disintegrin and Metalloprotease 10 Gene Polymorphisms in a Cohort of Egyptian Patients with Hepatocellular Carcinoma
Volume: 17
Issue: 4
Author(s): Amal A. Mohamed , Dina M. Abo-Elmatty , Omnia I ezzat , Ahmed A. Youssef , Eman T. Mehanna , Alshymaa A. Hassnine , Noha M. Mesbah, Salma Saed, Eman Al Sayed , Mahmoud Hamada , Afaf F. Khamis, Ayman Elshentenawy, Marwa S.E. Abd El-Raouf, Sherief Abd-Elsalam*Amr M. Elsayed
Affiliation:
- Tropical Medicine Department, Tanta University, Tanta,Egypt
Keywords:
Hepatocellular carcinoma (HCC), adisintegrin and metalloprotease (ADAMs), liver cirrhosis, single nucleotide polymorphisms
(SNP), HBV, HCV.
Abstract:
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality.
There is a need for a marker associated with HCC progression. A disintegrin and metalloprotease
(ADAMs) family proteins have a lot of functions in cell adhesion, migration, proteolysis and
signaling.
Aims: The aim of the study was to investigate the relation between ADAM 10 gene single nucleotide
polymorphisms (SNPs) and HCC progression.
Methods: This study involved 201 cases divided: Group I (67 HCC patients), Group II (67 cirrhotic
patients), Group III (67 control). Each group was subjected to laboratory investigations: (CBC,
blood sugar, kidney and liver function, viral markers, alpha fetoprotein), imaging: (abdominal ultrasonography,
and triphasic C.T) and ADAM 10 gene polymorphism (rs 653765, rs 383902) detection
by real – time PCR.
Results: There was a statistically significant difference in the frequency and genotyping of
ADAM10 SNPs in HCC patients in comparison to cirrhotic and control groups [the frequency of rs
653765 genotypes (p=0.015) and model (p=0.013)]; likewise, the frequency of rs 383902 genotypes
(p<0.001) and model (p=0.001)). Also, there was a statistically significant association between
different SNP rs 383902 genotype with CLIP stages (p=0.02) and with VISUM stages
(p=0.035).
Conclusion: ADAM-10 is overexpressed in HCC patients and involved in HCC progress. These
findings highlight that ADAM inhibitor may be used as therapeutic goals in the treatment of HCC.
